Portal de Periódicos da CAPES

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

2016; Massachusetts Medical Society; Volume: 375; Issue: 5 Linguagem: Inglês

10.1056/nejmoa1603144

1533-4406

Colin C. Pritchard, Joaquı́n Mateo, Michael F. Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind A. Eeles, Olivier Elemento, Mark A. Rubin, Dan R. Robinson, Robert J. Lonigro, Maha Hussain, Arul M. Chinnaiyan, Jake Vinson, Julie Filipenko, Levi A. Garraway, Mary‐Ellen Taplin, Saud H. AlDubayan, G. Celine Han, Mallory Beightol, Colm Morrissey, Belinda Nghiem, Heather H. Cheng, Bruce Montgomery, Tom Walsh, Silvia Casadei, Michael F. Berger, Liying Zhang, Ahmet Zehir, Joseph Vijai, Howard I. Scher, Charles L. Sawyers, Nikolaus Schultz, Philip W. Kantoff, David B. Solit, Mark E. Robson, Eliezer M. Van Allen, Kenneth Offit, Johann S. de Bono, Peter S. Nelson,

PARP inhibition in cancer therapy

Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established.